title: Intravitreal bevacizumab to treat choroidal neovascularization following photodynamic therapy in central serous choroidopathy.
abstract: OBJECTIVE
  To report the anatomic and functional outcome of intravitreal bevacizumab (IVB) to treat choroidal neovascularization (CNV) following photodynamic therapy (PDT) to treat recurrent central serous choroidopathy (CSC).
  
  
  METHODS
  This was an interventional case report in which verteporfin PDT was performed in a case of recurrent CSC.
  
  
  RESULTS
  Following PDT, the patient developed juxtafoveal CNV that was later treated by IVB, achieving CNV closure and recovery of visual acuity.
  
  
  CONCLUSIONS
  Photodynamic therapy is a useful therapy to treat recurrent CSC, though it may be associated with potentially severe complications such as CNV. Intravitreal bevacizumab seems a good alternative treatment in the management of this condition.
authors.affiliation: Vitreo-Retinal Unit, Alicante Institute of Ophthalmology, VISSUM, Alicante, Spain. javmonmor@hotmail.com
authors.forename: Javier A
authors.initials: JA
authors.lastname: Montero
authors.forename: José M
authors.initials: JM
authors.lastname: Ruiz-Moreno
authors.forename: Marta
authors.initials: M
authors.lastname: Fernandez-Muñoz
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000503:physiopathology; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D003131:Combined Modality Therapy; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D010778:Photochemotherapy / Q000009:adverse effects*; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012008:Recurrence; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D011166:Porphyrins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000077362:Verteporfin; D000068258:Bevacizumab